ROS1 abstracts at #WCLC19

Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10.  While the times and locations of sessions may change, the numbers and names will not. 

ES14 – What First Line in Oncogene Addicted NSCLC

    • 15:15 – 16:45
    • 9/08/2019
    • Location: Vancouver (2003)
    • Type: Educational Session
    • Track: Targeted Therapy
    • Moderators: Dolores Isla, Jessica Menis

ES14.03 – First Line in ROS1 Translocated Patients
15:45 – 16:00 Presenting Author(s): Frances Shepherd

Sunday Sep 8 ePosters (Exhibit Hall 0800-1800)

EP1.09-05 – Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 FISH Analysis in Lung Adenocarcinoma: Is IHC a Reliable Screening Tool?Track: Pathology
Presenting Author(s): Shivani Sharma  |  Author(s): Aditi DewanLata KiniMohit BhardwajShivmurti KumarDevender SharmaBrijpal Singh YadavRakesh PandeyKamakhya Gogai

EP1.14-33 – Intestinal Metastasis from Primary ROS1-Positive Lung Adenocarcinoma Patients Responding to Crizotinib
Track: Targeted Therapy
Presenting Author(s): Chunwei Xu  |  Author(s): Huafei ChenYoucai ZhuXiaofeng LiLixin WuKaiqi DuWenxian WangMeiyu Fang

EP1.14-45 – ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
Track: Targeted Therapy
08:00 – 08:00  |  Presenting Author(s): Chunwei Xu  |  Author(s): Xingliang LiShuguang XuWenxian WangJunhui YeYoucai ZhuTing GeMeiyu FangTangfeng LvYong Song

Sunday Sep 8 Poster Session (Exhibit Hall 0945-1800)

P1.01-56 – Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
Track: Advanced NSCLC
09:45 – 09:45  |  Presenting Author(s): Noemi Reguart  |  Author(s): Cristina AguadoCristina TeixidoAna Gimenez-CapitanElba MarinAna Peréz-RosadoCarlos CabreraRuth RománIrene MoyaSantiago ViteriRafael RosellMiguel Angel Molina-Vila

P1.01-83 – Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
Track: Advanced NSCLC
Presenting Author(s): Robert C. Doebele  |  Author(s): Laura PerezHuong TrinhMichael MartinecReynaldo MartinaTodd RiehlMatthew G KrebsNeal J. MeropolWill WongGracy Crane

P1.01-104 – Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib
Track: Advanced NSCLC
Presenting Author(s): Yu-Er Gao  |  Author(s): Chang LuHua-Jun ChenZhen WangBin-Chao WangXu-Chao ZhangChong-Rui XuYi-Long WuJin-Ji Yang

P1.14-03 – Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial
Track: Targeted Therapy
Presenting Author(s): Lorenza Landi  |  Author(s): marcello TiseoLukas C HeukampRoopika MenonGianluca SpitaleriDiego Luigi CortinovisAngelo DelmonteDomenico GalettaManolo D’ArcangeloFederica D’IncàMiriam BertrandBalázs JóriAngela ZacherCesare GridelliSilvia NovelloRita ChiariClaudio VerusioLucio CrinoFederico Cappuzzo

P1.14-12 – A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
Track: Targeted Therapy
Presenting Author(s): Hiroki Sato  |  Author(s): Adam J SchoenfeldEvan SiauKen SuzawaChristine YueMichael OffinAlexander DrilonMonika A DavareGregory J RielyMarc LadanyiRomel Somwar

P1.14-15 – Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Track: Targeted Therapy
Presenting Author(s): Umut Demirci  |  Author(s): Saadettin KilickapFatma Basal BugdayciDeniz TuralTaner KorkmazSemra PaydasCengiz YilmazHande TurnaAhmet SezerHavva Yesil CinkirKerem OkuturMustafa ErmanYesim EralpDevrim CabukAbdurrahman IsikdoganAhmet DemirkazikAziz KaraogluDogan YazilitasFiliz Cay SenlerPerran Fulden YumukHasan Senol CoskunIbrahim YildizIlhan OztopIsmail BeypinarKubra AydinMuhammed Ali KaplanNezih MeydanOmer Fatih OlmezOzgur OzyilkanSelcuk SeberCagatay ArslanMehmet Ali Nahit SendurIrfan Cicin

P1.14-29 – Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research
Track: Targeted Therapy
Presenting Author(s): Janet Freeman-Daily  |  Author(s): Bonnie AddarioColin BartonUpal Basu RoyShelley B BlamIvy ElkinsJill FeldmanAnita FiguerasRobert HanlonMarcia Karen HornPasi A JänneChristine M LovlyAmy MooreTerry L NgAlicia Sable-HuntSandra ShawRobert C. Doebele

P1.14-50 – A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma
Track: Targeted Therapy
Presenting Author(s): Robin Guo  |  Author(s): Isabel PreeshagulAdam J SchoenfeldCaroline G. McCarthyAlex MakhninAndrew J. PlodkowskiMichelle S. GinsbergMonika A DavareLukas DelasosRomel SomwarMaria E. ArcilaGregory J RielyNatasha RekhtmanMarc LadanyiMark G KrisAlexander Drilon

PC01 – Reinventing Clinical Trials

PC01.02 – Real World Research Groups – ROS1ders
11:15 – 11:30  |  Presenting Author(s): Merel Hennink

MA14 – The Adequate MTarget Is Still the Issue

MA14.02 – Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases

15:50 – 15:55  |  Presenting Author(s): Luis Paz-Ares  |  Author(s): Rafal DziadziuszkoAlexander DrilonTom JohnMatthew G KrebsGeorge DemetriAlice T. ShawSalvatore SienaJuergen WolfAnna F FaragoBrian SimmonsChenglin YeXinhui HuangRobert C. Doebele

MA22 – Partnering with Patients to Understand Stigma, Disparities and Values Leading to Improved Lung Cancer Care

MA22.03 – The ROS1ders: Partnering to Drive Research and Improve Outcomes in ROS1+ Cancers
15:55 – 16:00  |  Presenting Author(s): Janet Freeman-Daily  |  Author(s): Lisa GoldmanLysa BuonnanoTori Tomalia

Monday Sep 9 Poster Session (Exhibit Hall 1015-1815)

P2.03-07 – Frequency of Driver Genes (EGFR, KRAS, BRAF, ALK, RET and ROS1) Alterations in Brazilian Patients with Lung Adenocarcinoma
Track: Biology
Presenting Author(s): Letícia Ferro Leal  |  Author(s): Lazaro Antonio Campanha NovaesRodrigo de Oliveira CavagnaFlávia Escremim De PaulaPedro De MarchiMaicon Fernando Zanon Da SilvaAdriane Feijó EvangelistaLuciane Sussuchi Da SilvaEduardo Caetano Albino Da SilvaRui Manuel Reis

P2.03-27 – Discovery of WNK1-ROS1 Fusion in a Lung Adenocarcinoma Patient and the Precise Guidance for Targeted Therapies
Track: Biology
Presenting Author(s): Rui Lin  |  Author(s): Tianfeng LiuYutao LiuNan LiYUe PuTao Wang

P2.09-27 – Correlation Between Different ROS1 Clones (SP384 & D4D6) and Consistency with ROS1 Fluorescence in Situ Hybridization (FISH) Results
Track: Pathology
Presenting Author(s): Büge Aysim Öz  |  Author(s): Onur DulgerŞebnem Batur

P2.09-33 – Prevalence of ROS1 (SP384)-Reactive Type II Pneumocyte Staining in Lung Tissue
Track: Pathology
Presenting Author(s): Ina Menzl  |  Author(s): Catherine H LeRichard S.P. HuangTyler FoutchCharmi PatelAmy E. Hanlon NewellGreg Pate

P2.14-09 – Concurrent TP53 Mutation Adversely Impact the Efficacy of Crizotinib in ROS1-Rearranged Lung Cancer Patients

Track: Targeted Therapy
Presenting Author(s): Gen Lin  |  Author(s): Huamin XuJun ZhaoJinliang KongXinghao AiFenglei YuKaiqi DuLingjun ZhuLin LiHongxia MaQiaoli WangHuanhuan XiongRongrong ChenXuefeng Xia

P2.14-46 – Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
Track: Targeted Therapy
Presenting Author(s): Maximilian J. Hochmair  |  Author(s): Christoph WeinlingerHannah FabikanOliver IlliniDagmar KrenbekUlrike SetinekStefan WatzkaRenate KogerMichael MeilingerGudrun AbsengerMichael WankeChristoph SemmelweisMarkus RauterArschang Valipour

P2.14-61 – Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer
Track: Targeted Therapy
Presenting Author(s): Bo Mi Ku  |  Author(s): Hyun Ae JungJong-Mu SunSe-Hoon LeeJin Seok AhnKeunchil ParkMyung-Ju Ahn

P2.14-69 – Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non–Small Cell Lung Cancer (NSCLC)
Track: Targeted Therapy
Presenting Author(s): Aaron John Franke  |  Author(s): Viswam S NairMichael ShafiqueSepideh Mokhtari

P2.16-05 – Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System
Track: Treatment in the Real World – Support, Survivorship, Systems Research
Presenting Author(s): Maisam Makarem  |  Author(s): Doreen EzeifeAdam C SmithJennifer H LawMing Sound TsaoNatasha B Leighl

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.

One thought on “ROS1 abstracts at #WCLC19

Comments are closed.